diagnosed with Shingles recently and received the complete VARIVAX series at 1 year and 5 years old; This spontaneous report was received from a company representative referring to three patients of unspecified age and gender.  The patients' medical history, concurrent conditions and concomitant therapies were not reported.  On an unknown date, the patients were vaccinated with varicella virus vaccine live (Oka/Merck) (VARIVAX) injection, administered intramuscularly for varicella immunisation (strength, lot #, and expiry date were not provided).  On an unspecified date in 2023 (reported as "recently"), the patients were diagnosed with shingles despite completing varicella virus vaccine live (Oka/Merck) (VARIVAX) series (shingles).  At the time of reporting, the outcome of the event was not provided.  The causal relationship between the event and varicella virus vaccine live (Oka/Merck) (VARIVAX) was not established.  Follow-up information has been received from a registered nurse on 26-SEP-2023.   The reporter stated that there was a single patient to report, previously incorrectly reported as three patients. The patient was a 14-year-old male patient. He had two siblings. He had no known drug allergies and no significant past medical history. On 27-OCT-2009, the patient was vaccinated with the varicella virus vaccine live (Oka/Merck) (VARIVAX) (also reported as an unspecified varicella vaccine), pneumococcal vaccine conj 7v (crm197) (PREVNAR), measles, mumps, and rubella (WISTAR RA 27-3) virus vaccine, live (M-M-R II), and an unspecified haemophilus B conjugate vaccine (no additional vaccine information available). On 14-OCT-2013, the patient was vaccinated with measles, mumps, rubella and varicella (Oka-Merck) virus vaccine live (PROQUAD) and diphtheria vaccine toxoid, pertussis vaccine acellular 3-component, polio vaccine inact 3v (vero), tetanus vaccine toxoid (KINRIX) by a licensed practical nurse (no additional vaccine information available). There were no other vaccines documented as administered 4 weeks prior, no documented illness on the dates of vaccinations, no documented rash following any previous injections within 42 days of injections, and no previous reported adverse events following vaccinations. The patient had no history of chicken pox or herpes zoster, and there was no known exposure to chicken pox or herpes zoster. On 21-AUG-2023, the patient presented to the health care provider office on with a rash along the lumbar (L2) dermatome that was distributed down to the patient's left knee. The reporter stated there were greater than 500 lesions, pain was recorded as 8/10, and temperature was 99.0 degrees Fahrenheit. The patient was prescribed wvalaciclovir hydrochloride (VALTREX) with full resolution of the rash by 02-SEP-2023. A varicella zoster by molecular assay was performed, but specific results were not available. No additional testing was documented. The reporter was asked to collect a sample of the patient's rashes, but the reporter stated that there were no more rashes and these were past scenarios. The causal relationship between all suspect vaccines and the event was not reported.  This case was previously considered as non-valid due to lack of patient identifiers, but upon receipt of follow-up it was determined that the case is now valid.